Eye drops and preparation method thereof

Abstract

The invention provides eye drops and a preparation method thereof, and relates to the eye drops. The invention provides the eye drops which have the advantages of shorter action time, lower cost, better effect and capacity of resisting corneal neovascularization and quickly repairing epithelium compared with the conventional eye drops, and a preparation method thereof. The eye drops comprise the following components in percentage by volume: 0.1 to 5 percent of bovine serum, 5 to 15 percent of thickener, 1 to 5 percent of pH regulation solution, 0.1 to 2 percent of osmotic pressure buffer, 0.5 to 2 percent of antibiotic, 5 to 30 percent of original solution of kallikrein-binding protein (SA3K) and the balance of balanced salt solution. According to a prescription of the eye drops, the preparation method comprises the following steps of: adding the thickener, the bovine serum, the antibiotic and the original solution of SA3K into the balanced salt solution; uniformly mixing; regulating the pH value to be 7.2 to 7.4 by using the pH regulator; regulating the osmotic pressure to be 350 to 380mOsm / L by using the osmotic pressure buffer; and filtering and degerming by using a membrane to obtain the SA3K eye drops.

Description

technical field [0001] The invention relates to an eye drop, in particular to an eye drop for treating inflammatory corneal neovascularization and corneal epithelial defect diseases and a preparation method thereof. Background technique [0002] Corneal disease is one of the common blinding eye diseases. Clinically, corneal inflammation and corneal damage caused by various factors can cause corneal defect, erosion and ulcer. If not treated effectively, it will seriously damage the visual function of the patient and quality of life. According to the report of the World Health Organization, at present, corneal disease is the second major cause of vision loss, second only to cataract, and the number of new corneal blindness caused by corneal ulcer and ocular trauma is (1.5-2 million) every year, which is a serious threat. It is the social responsibility of Chinese ophthalmologists to carry out in-depth prevention and treatment of blindness. Chinese Journal of Ophthalmology, 20...

AI Technical Summary

Problems solved by technology

[0005] At present, there are no eye drops products for anti-inflammation, epithelial repair and anti-new blood vessels on the market. Most ophthalmic drugs used clinically have limited therapeutic functions, and there may be factors that influence and restrict each other in various drug components. In addition, the toxic ingredients and preservatives in various combined eye drops will damage the ocular surface microenvironment, make the existing ocular surface diseases worse, and bring certain confusion to the treatment of various corneal diseases; in addition, large Most anti-inflammatory products contain hormone ingredients, long-term use can seriously affect the ocular surface microenvironment of patients, and some anti-inflammatory drugs have related complications, such as large doses of chloramphenicol eye drops can cause eyelid and corneal edema, Restricted eye movement and optic disc atrophy, long-term application can cause aplastic anemia, etc.; anti-neovascular drugs, such as artesunate ([20] Chen Huanhuan, Zhou Huijun. The anti-angiogenic effect of artesunate. Acta Pharmaceutica 2004 ; 39(1): 29-33) eye drops, the composition is more complex, the effect is not sure enough, and there is no anti-inflammatory and anti-lymphatic effect; doxycycline eye drops is currently an effective drug for treating inflammation, but currently there is no No formally commercialized preparations

Images